Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0409974 (lupus)
 22,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Karl Wilhelm Kalkoff (1909-1981) describes in his unpublished memoirs the first cure of a female patient suffering from a severe form of tuberculosis cutis of the lupus vulgaris type. The drug used in this case was TBI/698 developed by Bayer Leverkusen, which was later named Conteben. This was the first chemotherapeutic cure of tuberculosis.
 ...
PMID:[The first tuberculosis cure with chemotherapy: a lupus patient in Hornheide]. 752 Oct 54

Leprosy was nearly eliminated in central Europe by the beginning of 18th century. In the 2nd half of the 19th century, leprosy was imported by Lithuanian rural workers immigrating from the Russian empire into East Prussia. At that time, the ways of infection, the bacteria, and essential diagnostic methods were already known, but there was no effective treatment. A leprosarium was founded in 1899 in Memel. Legislation in 1900 and 1904 regulated the fight against the disease. The patients had to be isolated and not allowed to work with others, in contrast to the situation with cutaneous tuberculosis. Patients with lupus vulgaris, which was not infectious, even had suitable jobs in hospitals. In 1907, Antileprol (Bayer) became available, the first industrial preparation developed from chaulmoogra oils, which had been long used in Indian medicine. The situation of patients, however, remained nearly unchanged, up to the middle of the 20th century, when the first effective mycobacteriostatic agents were introduced.
 ...
PMID:[Leprosy in Germany 100 years and the early development of anti-leprosy drugs]. 1767 59

Chloroquine (CQ), N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine, is widely used as an effective and safe anti-malarial and anti-rheumatoid agent. CQ was discovered 1934 as "Resochin" by Andersag and co-workers at the Bayer laboratories. Ironically, CQ was initially ignored for a decade because it was considered too toxic to use in humans. CQ was "re-discovered" during World War II in the United States in the course of anti-malarial drug development. The US government-sponsored clinical trials during this period showed unequivocally that CQ has a significant therapeutic value as an anti-malarial drug. Consequently, CQ was introduced into clinical practice in 1947 for the prophylaxis treatment of malaria (Plasmodium vivax, ovale and malariae). CQ still remains the drug of choice for malaria chemotherapy because it is highly effective and well tolerated by humans. In addition, CQ is widely used as an anti-inflammatory agent for the treatment of rheumatoid arthritis, lupus erythematosus and amoebic hepatitis. More recently, CQ has been studied for its potential as an enhancing agent in cancer therapies. Accumulating lines of evidence now suggest that CQ can effectively sensitize cell-killing effects by ionizing radiation and chemotherapeutic agents in a cancer-specific manner. The lysosomotrophic property of CQ appears to be important for the increase in efficacy and specificity. Although more studies are needed, CQ may be one of the most effective and safe sensitizers for cancer therapies. Taken together, it appears that the efficacy of conventional cancer therapies can be dramatically enhanced if used in combination with CQ and its analogs.
 ...
PMID:Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. 1983 74